Baudax Bio Announces Proposed Public Offering of Securities

Feb 24, 2022 4:40pm EST

Baudax Bio Announces 1-for-35 Reverse Stock Split

Feb 15, 2022 8:29pm EST

Baudax Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Jan 04, 2022 7:00am EST

Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 31, 2021 4:05pm EST

Baudax Bio Announces $4.2 Million Registered Direct Offering

Dec 28, 2021 8:00am EST

Baudax Bio to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

Nov 15, 2021 7:00am EST

Baudax Bio Announces Clinical Program Update for Neuromuscular Blocking Agents BX-1000, BX-2000 and BX-3000

Nov 11, 2021 7:00am EST

Baudax Bio Reports Third Quarter 2021 Financial Results and Business Highlights

Nov 04, 2021 7:00am EDT

Baudax Bio to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4, 2021

Oct 28, 2021 7:00am EDT

Baudax Bio to Present at the NobleCon Pain Management Investor Forum

Oct 05, 2021 7:00am EDT